( insulin glargine 100 U / mL )
Thank you Lantus ®
( insulin glargine 100 U / mL )
Same formulation of insulin glargine 100 U / mL and SoloStar ® pen as Lantus 1
Make the switch to Optisulin with confidence . From the makers of Lantus . 1
Optisulin is Sanofi ’ s only brand of insulin glargine 100 U / mL on the PBS since 1 July 2020 2 , 3
Use the QR code to download the MedEye app to view the Optisulin Augmented Reality Experience , select Sanofi , then view the billboards through your phone camera .
PBS information : Lantus ® SoloStar ® and Lantus ® cartridges were delisted from the PBS on 1st July 2020 .
PBS information : Optisulin ® SoloStar ® and Optisulin ® cartridges are listed on the PBS as a long-acting insulin analogue for the treatment of type 1 and adults with type 2 diabetes .
Please review Product Information before prescribing Optisulin . Full Product Information is available at http :// www . guildlink . com . au / gc / ws / sw / pi . cfm ? product = swpoptis or by calling 1800 818 806 .
Minimum Product Information : Lantus ( insulin glargine 100 units / mL ) and Optisulin ( insulin glargine 100 units / mL ) Indications : Once-daily subcutaneous administration for type 1 diabetes mellitus patients ( adults and children ) and type 2 diabetes mellitus patients ( adults ) who require insulin for control of hyperglycaemia . Contraindications : Hypersensitivity to insulin glargine or any excipient . Precautions : Hypoglycaemia ; hepatic , renal and visual impairment ; lipodystrophy and other injection site reactions ; antibody production ; intercurrent conditions ; not studied in children < 2 years , pregnancy category B3 , lactation ; not intended for i . v . use ; not recommended for treatment of diabetic ketoacidosis ; LANTUS AND OPTISULIN MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION . Instruct patient to check insulin label before each injection to avoid accidental mix-ups between insulins . Interactions : Oral antidiabetic agents ; cardiovascular , analgaesic , anti-inflammatory , neurological , antipsychotic agents ( see full PI ); antibiotics ; corticosteroids , other hormonal therapies ( see full PI ); diuretics ; protease inhibitors ; sympathomimetic agents ; lithium ; alcohol ; sympatholytics including β-blockers ; others , see full PI . Side effects : Hypoglycaemia ; injection site reactions ; visual disturbances ; others , see full PI . Dosage and Administration : ≥6 years . Subcutaneous , once daily . Lantus and Optisulin are equipotent to human insulin . Initial dose determined depending on desired blood glucose levels and doses and timing of any antidiabetic medication . For changeover from once daily NPH or ultralente , initial dose usually not changed ; for changeover from twice-daily NPH to once-daily Lantus or Optisulin , initial dose usually reduced by approximately 20 % compared to total daily NPH dose ; for initiation of type 2 patients , initial dose usually approximately 10 IU . For changeover from once daily insulin glargine 300 units / mL to once daily Lantus or Optisulin , recommended initial dose is approximately 80 % of insulin glargine 300 units / mL that is being discontinued . Date reviewed : 03 December 2019 . Reference Document : PI , 03 December 2019 .
References : 1 . Optisulin Product Information . 2 . Sanofi . Data on file . 3 . Pharmaceutical Benefits Scheme . Optisulin . www . pbs . gov . au / pbs / search ? term = optisulin [ accessed 04 Feb 2020 ]. Further information is available from Sanofi on request . ® Optisulin , Lantus and SoloStar are registered trademarks of sanofi-aventis australia pty ltd . sanofi-aventis australia pty ltd trading as Sanofi , ABN 31 008 558 807 , Talavera Corporate Centre , Building D , 12 – 24 Talavera Road , Macquarie Park , NSW 2113 . Vivacity H _ SAVO026 Date of preparation : May 2020 SAANZ . GLA . 20.02.0052f